On Monday, Pliant Therapeutics Inc. PLRX introduced the discontinuation of the BEACON-IPF Part 2b trial, which evaluated bexotegrast in sufferers with idiopathic pulmonary fibrosis (IPF).
The transfer follows a prespecified information evaluation and suggestion by the trial’s unbiased Knowledge Security Monitoring Board and a secondary evaluation and suggestion by an out of doors knowledgeable panel.
Needham downgraded Pliant Therapeutics, citing no significant catalysts or upside drivers over the following 12 months.
Additionally Learn: MDJM Debuts Its E-Commerce Platform: Particulars
Needham analyst Joseph Stringer writes that the IPF program was the primary worth driver for Pliant Therapeutics.
The rest of the pipeline is comparatively skinny and in early-stage growth.
Needham has downgraded from Purchase to Maintain, with no value goal assigned in comparison with $10 beforehand.
With the stopped IPF program, the replace has created a big problem if the drug is taken into account for different situations.
Pliant Therapeutics notes that bexotegrast confirmed some effectiveness within the IPF trial, leaving room for potential dose-ranging research to enhance its benefit-risk profile—presumably even in IPF once more.
Nevertheless, this may be a protracted and tough course of with unsure prospects. Bexotegrast has additionally proven promise in main sclerosing cholangitis (PSC), however its growth on this situation carries dangers.
Value Motion: PLRX inventory is up 0.36% at $1.38 eventually verify Monday.
Learn Subsequent:
Photograph: Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
